Anita T. Shaffer

Associate Director of Editorial, Print
Anita T. Shaffer is your lead editorial contact for OncologyLive®, a twice monthly clinical news publication. A 10-year veteran of MJH Life Sciences™, she has been at the helm of the publication since shortly after joining the company in 2010. Before becoming an oncology journalist, she held a variety of editorial positions at The Times of Trenton, including metro editor. Email:


Targeted Combo Notches Rare Success in Glioblastoma

March 30th 2022

Encouraging response rates to a dual-targeted regimen in patients with recurrent or refractory malignant brain tumors with BRAF V600E mutations were reported in 2021, representing a new potential targeted therapy strategy against glioblastoma.

Checkpoint Inhibitor Changes Take Hold: Approval Standards Stir Debate

February 16th 2022

the development of PD-1/PD-L1 immune checkpoint inhibitor therapy underwent a course correction in 2021, with the withdrawal of a range of indications due to study results that failed to reach thresholds for confirming clinical benefit.

New Strategies Are Needed for Patients With NRAS-Mutant Melanoma

November 3rd 2021

Although there has been dramatic progress in the treatment landscape for metastatic melanoma over the past decade, many patients whose tumors harbor NRAS mutations have not shared in the improved outcomes.

IO Combo Anchors a New Front Line Taking Shape in Unresectable HCC

October 13th 2021

The tide is starting to turn toward more effective frontline systemic therapies for patients with unresectable hepatocellular carcinoma as a result of the introduction of a novel immune-oncology combination.

Novel Drug Sparks Hope for Targeting HER3 in NSCLC and Beyond

October 11th 2021

Patritumab deruxtecan, a novel antibody-drug conjugate, is emerging as a promising HER3-directed therapy in patients with non–small cell lung cancer and perhaps other solid malignancies.

3 Precision Era Biomarkers Get a Closer Look

August 18th 2021

Circulating tumor DNA, tumor mutational burden, and homologous recombination deficiency are 3 emerging biomarkers for tailoring therapy need further clinical and technical clarity to support robust use in daily practice.

CEACAM5 Joins a Growing Menu of Emerging Lung Cancer Targets

August 3rd 2021

After nearly two decades of successfully developing therapies directed at molecular aberrations in non–small cell lung cancer, investigators are exploring a new generation of novel targets, including some not specifically associated with driver mutations.

Navitoclax Shows Early Signs of Clinical Benefit in Myelofibrosis

April 1st 2021

The combination of navitoclax and ruxolitinib simultaneously inhibits 2 key mechanisms that promote myelofibrosis, resulting in an improvement in symptom control and positive changes in response biomarkers in patients with high-risk disease.

FDA Will Reassess 6 Immunotherapy Accelerated Approvals

March 12th 2021

Six indications for immune checkpoint inhibitors granted under the FDA’s accelerated approval process that later failed confirmatory clinical trials are being reassessed as the agency continues an industry-wide evaluation of the pathway.

Margetuximab Approval Augments Emerging Treatment Choices in Breast Cancer

March 8th 2021

Margetuximab represents an effective new therapeutic option that can be combined safely with a chemotherapy drug of choice for patients with metastatic HER2-positive breast cancer who have undergone multiple lines of prior treatment.

First BCMA-Targeting Therapy Debuts in Multiple Myeloma

January 20th 2021

Sagar Lonial, MD, discussed key facets of belantamab mafodotin and potential next steps.

Off-the-Shelf CAR Therapy Shows Early Promise in Multiple Myeloma

December 5th 2020

ALLO-715, an off-the-shelf chimeric antigen receptor T-cell therapy that targets B-cell maturation antigen, elicited responses in heavily pretreated patients with relapsed/refractory multiple myeloma in early findings from a first-in-human study presented at the 2020 ASH Meeting.

Mato Presents Sequencing Framework for Crowded CLL Landscape

November 4th 2020

An explosion of therapeutic options for chronic lymphocytic leukemia has resulted in challenging questions about sequencing therapies for patients who progress after frontline treatment with little data to guide optimal therapy selection.

BCMA-Targeting Drugs Take Center Stage in Myeloma

November 4th 2020

The treatment landscape for multiple myeloma is poised to enter a new era of innovation with the development of therapies that target B-cell maturation antigen, which is highly expressed on plasma and MM cells.

Three Key ASCO Studies Showcase Targeted Advances

July 15th 2020

Molecularly targeted therapies showed practice-changing results for patients with biomarker-driven lung, colorectal, and ovarian cancers in phase 3 randomized clinical trial findings.

Frontline Durvalumab Maintains OS Benefit in Extensive-Stage Small Cell Lung Cancer

May 31st 2020

The addition of durvalumab to standard chemotherapy continued to demonstrate an improvement in overall survival for patients with treatment-naïve extensive-stage small cell lung cancer.

CDK4/6 Inhibitors Reach New Benchmarks in Overall Survival in HR+ Breast Cancer

March 6th 2020

The release of new evidence that CDK4/6 inhibition results in survival gains for patients with hormone receptor–positive, HER2-negative metastatic breast cancer marks a new milestone for the therapeutic approach and may help set the stage for expanding use of these agents into earlier clinical settings.

Triplet Targeted Therapy May Signal a New Standard in Metastatic CRC

July 17th 2019

Now, investigators are combining BRAF inhibitors with other targeted therapies in an effort to establish a new chemotherapy-free standard in patients with metastatic colorectal cancer.

Preoperative Immunotherapy Sends Positive Signals in 2 NSCLC Studies

June 3rd 2019

Neoadjuvant immunotherapy demonstrated substantial activity with a favorable toxicity profile in findings from 2 studies of patients with operable early-stage non–small cell lung cancer reported at the 2019 ASCO Annual Meeting.

Antibody-Drug Conjugates Make Headway in TNBC

March 10th 2019

The development of antibody-drug conjugates represents a promising strategy for patients with metastatic triple-negative breast cancer, with early clinical trial results suggesting that novel agents could eventually change the landscape for this patient population.